| Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation JC Nault, G Couchy, C Balabaud, G Morcrette, S Caruso, JF Blanc, ... Gastroenterology 152 (4), 880-894. e6, 2017 | 363 | 2017 |
| Liver cancer initiation requires p53 inhibition by CD44-enhanced growth factor signaling D Dhar, L Antonucci, H Nakagawa, JY Kim, E Glitzner, S Caruso, ... Cancer cell 33 (6), 1061-1077. e6, 2018 | 181 | 2018 |
| Potential role of ANGPTL4 in the cross talk between metabolism and cancer through PPAR signaling pathway L La Paglia, A Listì, S Caruso, V Amodeo, F Passiglia, V Bazan, D Fanale PPAR research 2017, 2017 | 160 | 2017 |
| Clinical impact of genomic diversity from early to advanced hepatocellular carcinoma JC Nault, Y Martin, S Caruso, TZ Hirsch, Q Bayard, J Calderaro, C Charpy, ... Hepatology 71 (1), 164-182, 2020 | 155 | 2020 |
| Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response S Caruso, AL Calatayud, J Pilet, T La Bella, S Rekik, S Imbeaud, ... Gastroenterology 157 (3), 760-776, 2019 | 154 | 2019 |
| Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma C Péneau, S Imbeaud, T La Bella, TZ Hirsch, S Caruso, J Calderaro, ... Gut 71 (3), 616-626, 2022 | 123 | 2022 |
| Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis A Filliol, Y Saito, A Nair, DH Dapito, LX Yu, A Ravichandra, ... Nature 610 (7931), 356-365, 2022 | 117 | 2022 |
| High density of tryptase‐positive mast cells in human colorectal cancer: a poor prognostic factor related to protease‐activated receptor 2 expression A Malfettone, N Silvestris, C Saponaro, G Ranieri, A Russo, S Caruso, ... Journal of cellular and molecular medicine 17 (8), 1025-1037, 2013 | 103 | 2013 |
| Adeno-associated virus in the liver: natural history and consequences in tumour development T La Bella, S Imbeaud, C Peneau, I Mami, S Datta, Q Bayard, S Caruso, ... Gut 69 (4), 737-747, 2020 | 102 | 2020 |
| Dual targeting of histone methyltransferase G9a and DNA‐methyltransferase 1 for the treatment of experimental hepatocellular carcinoma M Bárcena‐Varela, S Caruso, S Llerena, G Álvarez‐Sola, I Uriarte, ... Hepatology 69 (2), 587-603, 2019 | 97 | 2019 |
| Genetics of hepatocellular carcinoma: approaches to explore molecular diversity S Caruso, DR O’Brien, SP Cleary, LR Roberts, J Zucman‐Rossi Hepatology 73, 14-26, 2021 | 84 | 2021 |
| Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival L Quetel, C Meiller, JB Assié, Y Blum, S Imbeaud, F Montagne, ... Molecular oncology 14 (6), 1207-1223, 2020 | 84 | 2020 |
| Polyploidy spectrum: a new marker in HCC classification M Bou-Nader, S Caruso, R Donne, S Celton-Morizur, J Calderaro, ... Gut 69 (2), 355-364, 2020 | 84 | 2020 |
| Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open … YA Vano, R Elaidi, M Bennamoun, C Chevreau, D Borchiellini, D Pannier, ... The Lancet Oncology 23 (5), 612-624, 2022 | 83 | 2022 |
| microRNA 193a-5p regulates levels of nucleolar-and spindle-associated protein 1 to suppress hepatocarcinogenesis S Roy, GJ Hooiveld, M Seehawer, S Caruso, F Heinzmann, AT Schneider, ... Gastroenterology 155 (6), 1951-1966. e26, 2018 | 83 | 2018 |
| ESM1 as a marker of macrotrabecular-massive hepatocellular carcinoma J Calderaro, L Meunier, CT Nguyen, M Boubaya, S Caruso, A Luciani, ... Clinical Cancer Research 25 (19), 5859-5865, 2019 | 73 | 2019 |
| Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target M Ningarhari, S Caruso, TZ Hirsch, Q Bayard, A Franconi, AL Védie, ... Journal of Hepatology 74 (5), 1155-1166, 2021 | 69 | 2021 |
| The interplay between metabolism, PPAR signaling pathway, and cancer D Fanale, V Amodeo, S Caruso PPAR research 2017, 2017 | 67 | 2017 |
| Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer C Rolfo, D Fanale, D S Hong, A M Tsimberidou, S A Piha-Paul, P Pauwels, ... Current pharmaceutical biotechnology 15 (5), 475-485, 2014 | 57 | 2014 |
| BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA TZ Hirsch, A Negulescu, B Gupta, S Caruso, B Noblet, G Couchy, ... Journal of Hepatology 72 (5), 924-936, 2020 | 56 | 2020 |
